Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia.

ABSTRACT:

Background

The immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines is variable in individuals with different inborn errors of immunity or acquired immune deficiencies and is yet unknown in people with idiopathic CD4 lymphopenia (ICL).

Objective

We sought to determine the immunogenicity of mRNA vaccines in patients with ICL with a broad range of CD4 T-cell counts.

Methods

Samples were collected from 25 patients with ICL and 23 age- and sex-matched healthy volunteers (HVs) after their second or third SARS-CoV-2 mRNA vaccine dose. Anti-spike and anti-receptor binding domain antibodies were measured. T-cell receptor sequencing and stimulation assays were performed to quantify SARS-CoV-2-specific T-cell responses.

Results

The

SUBMITTER: Rocco JM 

PROVIDER: S-EPMC10861932 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature